Impax to Sell Authorized Generic Renvela - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:14PM CDT
Impax has started shipping the authorized generic version of Sanofi's Renvela (800 mg) under its settlement agreement with the latter.
Dr. Reddy's Launches Generic Lunesta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:44AM CDT
Dr. Reddy's Labs announced the launch of its therapeutic equivalent generic version of Sunovion Pharmaceuticals Inc.'s Lunesta tablets
Legal Settlement for Astellas Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:41AM CDT
Astellas Pharma announced that it has reached an agreement with the U.S. DOJ to resolve civil claims regarding the marketing of Mycamine for injection
Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.
Impax introduces generic RENVELA in the market
M2 - Thu Apr 17, 5:13AM CDT
Pharmaceutical company Impax Laboratories (NasdaqGS :IPXL) reported on Wednesday the shipment of its authorised generic RENVELA (sevelamer carbonate 800 mg tablets) for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
Impax Launches Authorized Generic RENVELA®
PR Newswire - Wed Apr 16, 8:10AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of authorized generic RENVELA (sevelamer carbonate 800 mg tablets), through Global Pharmaceuticals, Impax's generics division. RENVELA is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
Regulatory Update from Impax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:55PM CDT
Impax resubmitted a new drug application (NDA) for Rytary for the symptomatic treatment of Parkinson's disease (PD).
Impax Breathes New Life Into Stalled Parkinson's Drug
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 14, 8:30AM CDT
Investors had high hopes when Impax filed for FDA approval of IPX066, or Rytary, an extended release version of a common Parkinson's drug therapy, in 2011. But manufacturing woes dashed the drug's chances for an FDA approval, and ultimately...
Impax Pharmaceuticals Resubmits New Drug Application for RYTARY(TM) (Carbidopa and Levodopa) Extended-Release Capsules (IPX066)
PR Newswire - Fri Apr 11, 6:15AM CDT
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease (PD).
Mallinckrodt plc (MNK) in Focus: Stock Moves 5.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:37AM CDT
Mallinckrodt plc as the company saw its shares rise more than 5% on the day.
Pacira and Patheon Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:10PM CDT
Pacira has signed a strategic co-production partnership deal with Patheon.
Additional Data on Pacira's Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:20PM CDT
Pacira announced additional phase III data on its lead product, Exparel.
Health Care Sector Stocks under Review -- Research on Sanofi, Impax Laboratories, Keryx Biopharma, and Rigel Pharma
PR Newswire - Tue Apr 08, 12:59PM CDT
The trading session on Monday, April 07, 2014 ended on a lower note as the S&P 500 finished the session 1.08% lower at 1,845.04 and the NASDAQ Composite closed at 4,079.75, down 1.16%. The Dow Jones Industrial Average finished at 16,245.87, down 1.02%. During the session, nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 664.68, down 1.06%, and the same has declined 2.85% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Sanofi (NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) and Rigel Pharmaceuticals Inc. (NASDAQ: RIGL). Free technical research on SNY, IPXL, KERX and RIGL can be downloaded upon signing up at:
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2014 Financial Results
PR Newswire - Mon Apr 07, 7:15AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 4:30 p.m., Eastern Time on May 1, 2014.
Actavis Up Slightly on Silom Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 2:56PM CDT
Actavis acquired Thailand-based generic company, Silom Medical Company.
Impax Laboratories Announces the Alignment of Quality and Manufacturing Operations Under the Leadership of Jeffrey D. Nornhold
PR Newswire - Wed Apr 02, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Jeffrey D. Nornhold has been appointed Senior Vice President, Technical Operations and will oversee the Company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the Company's Senior Vice President, Global Quality Affairs since March 2011.
Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:00PM CDT
Pacira Pharma's shares gained 10.7% after the FDA approved of an additional manufacturing suite (Suite C) for Exparel.
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma, Sanofi and Impax Laboratories
PR Newswire - Wed Mar 19, 7:41AM CDT
On Tuesday, March 18, 2014, the NASDAQ Composite ended at 4,333.31, up 1.25%, the S&P 500 advanced 0.72% to 1,872.25, and the Dow Jones Industrial Average closed at 16,336.19, up 0.55%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 688.96, up 1.17%, and the same has advanced 1.47% in the last one month. Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Sanofi (NYSE: SNY) and Impax Laboratories Inc. (NASDAQ: IPXL). Free technical research on KERX, RIGL, SNY and IPXL can be downloaded upon signing up at:
Impax Laboratories Has Returned 18.4% Since SmarTrend Recommendation (IPXL)
Comtex SmarTrend(R) - Mon Mar 17, 9:23AM CDT
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on February 19th, 2014 at $24.00. In approximately 4 weeks, Impax Laboratories has returned 18.39% as of today's recent price of $28.42.